STOCK TITAN

[Form 4] Soligenix, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 Filing Details: Jerome B. Zeldis, Director of Soligenix (SNGX), reported the acquisition of stock options on June 20, 2025. The insider was granted 17,647 stock options with an exercise price of $1.70 per share.

The options have a 10-year term expiring on June 20, 2035, and will vest in four equal installments on:

  • September 20, 2025
  • December 20, 2025
  • March 20, 2026
  • June 20, 2026

This equity-based compensation grant aligns the director's interests with shareholders through long-term stock ownership potential. The filing was reported within the required SEC timeline, demonstrating compliance with Section 16(a) reporting obligations.

Dettagli della Comunicazione Modulo 4: Jerome B. Zeldis, Direttore di Soligenix (SNGX), ha comunicato l'acquisizione di opzioni su azioni il 20 giugno 2025. L'insider ha ricevuto 17.647 opzioni su azioni con un prezzo di esercizio di 1,70 $ per azione.

Le opzioni hanno una scadenza di 10 anni che termina il 20 giugno 2035 e matureranno in quattro tranche uguali nelle seguenti date:

  • 20 settembre 2025
  • 20 dicembre 2025
  • 20 marzo 2026
  • 20 giugno 2026

Questa concessione di compensi basata su azioni allinea gli interessi del direttore con quelli degli azionisti, favorendo un potenziale investimento azionario a lungo termine. La comunicazione è stata effettuata entro i termini richiesti dalla SEC, dimostrando la conformità agli obblighi di segnalazione della Sezione 16(a).

Detalles de la Presentación del Formulario 4: Jerome B. Zeldis, Director de Soligenix (SNGX), reportó la adquisición de opciones sobre acciones el 20 de junio de 2025. El insider recibió 17,647 opciones sobre acciones con un precio de ejercicio de $1.70 por acción.

Las opciones tienen un plazo de 10 años que expira el 20 de junio de 2035, y se consolidarán en cuatro cuotas iguales en las siguientes fechas:

  • 20 de septiembre de 2025
  • 20 de diciembre de 2025
  • 20 de marzo de 2026
  • 20 de junio de 2026

Esta concesión de compensación basada en acciones alinea los intereses del director con los de los accionistas mediante el potencial de propiedad accionaria a largo plazo. La presentación se realizó dentro del plazo requerido por la SEC, demostrando cumplimiento con las obligaciones de reporte de la Sección 16(a).

서식 4 제출 세부사항: Soligenix(SNGX)의 이사인 Jerome B. Zeldis는 2025년 6월 20일에 주식매수선택권 취득을 보고했습니다. 내부자는 주당 1.70달러의 행사 가격으로 17,647 주식매수선택권을 부여받았습니다.

이 옵션은 10년 만기로 2035년 6월 20일에 만료되며, 다음 네 차례에 걸쳐 동일한 비율로 권리가 부여됩니다:

  • 2025년 9월 20일
  • 2025년 12월 20일
  • 2026년 3월 20일
  • 2026년 6월 20일

이 주식 기반 보상 부여는 이사의 이익을 주주와 일치시키며 장기적인 주식 소유 가능성을 제공합니다. 제출은 SEC 요구 기간 내에 이루어져 섹션 16(a) 보고 의무를 준수함을 보여줍니다.

Détails du dépôt du formulaire 4 : Jerome B. Zeldis, directeur de Soligenix (SNGX), a déclaré l'acquisition d'options d'achat d'actions le 20 juin 2025. L'initié a reçu 17 647 options d'achat d'actions avec un prix d'exercice de 1,70 $ par action.

Les options ont une durée de 10 ans, expirant le 20 juin 2035, et seront acquises en quatre versements égaux aux dates suivantes :

  • 20 septembre 2025
  • 20 décembre 2025
  • 20 mars 2026
  • 20 juin 2026

Cette attribution de rémunération en actions aligne les intérêts du directeur avec ceux des actionnaires via un potentiel de détention d'actions à long terme. Le dépôt a été effectué dans les délais requis par la SEC, démontrant la conformité aux obligations de déclaration de la Section 16(a).

Details zur Form 4 Einreichung: Jerome B. Zeldis, Direktor von Soligenix (SNGX), meldete am 20. Juni 2025 den Erwerb von Aktienoptionen. Dem Insider wurden 17.647 Aktienoptionen mit einem Ausübungspreis von 1,70 $ pro Aktie gewährt.

Die Optionen haben eine Laufzeit von 10 Jahren und laufen am 20. Juni 2035 ab. Sie werden in vier gleichen Raten zu folgenden Terminen unverfallbar:

  • 20. September 2025
  • 20. Dezember 2025
  • 20. März 2026
  • 20. Juni 2026

Diese aktienbasierte Vergütung richtet die Interessen des Direktors mit denen der Aktionäre durch langfristiges Aktienbesitzpotenzial aus. Die Meldung erfolgte fristgerecht gemäß den Anforderungen der SEC und entspricht den Berichtspflichten gemäß Abschnitt 16(a).

Positive
  • None.
Negative
  • None.

Dettagli della Comunicazione Modulo 4: Jerome B. Zeldis, Direttore di Soligenix (SNGX), ha comunicato l'acquisizione di opzioni su azioni il 20 giugno 2025. L'insider ha ricevuto 17.647 opzioni su azioni con un prezzo di esercizio di 1,70 $ per azione.

Le opzioni hanno una scadenza di 10 anni che termina il 20 giugno 2035 e matureranno in quattro tranche uguali nelle seguenti date:

  • 20 settembre 2025
  • 20 dicembre 2025
  • 20 marzo 2026
  • 20 giugno 2026

Questa concessione di compensi basata su azioni allinea gli interessi del direttore con quelli degli azionisti, favorendo un potenziale investimento azionario a lungo termine. La comunicazione è stata effettuata entro i termini richiesti dalla SEC, dimostrando la conformità agli obblighi di segnalazione della Sezione 16(a).

Detalles de la Presentación del Formulario 4: Jerome B. Zeldis, Director de Soligenix (SNGX), reportó la adquisición de opciones sobre acciones el 20 de junio de 2025. El insider recibió 17,647 opciones sobre acciones con un precio de ejercicio de $1.70 por acción.

Las opciones tienen un plazo de 10 años que expira el 20 de junio de 2035, y se consolidarán en cuatro cuotas iguales en las siguientes fechas:

  • 20 de septiembre de 2025
  • 20 de diciembre de 2025
  • 20 de marzo de 2026
  • 20 de junio de 2026

Esta concesión de compensación basada en acciones alinea los intereses del director con los de los accionistas mediante el potencial de propiedad accionaria a largo plazo. La presentación se realizó dentro del plazo requerido por la SEC, demostrando cumplimiento con las obligaciones de reporte de la Sección 16(a).

서식 4 제출 세부사항: Soligenix(SNGX)의 이사인 Jerome B. Zeldis는 2025년 6월 20일에 주식매수선택권 취득을 보고했습니다. 내부자는 주당 1.70달러의 행사 가격으로 17,647 주식매수선택권을 부여받았습니다.

이 옵션은 10년 만기로 2035년 6월 20일에 만료되며, 다음 네 차례에 걸쳐 동일한 비율로 권리가 부여됩니다:

  • 2025년 9월 20일
  • 2025년 12월 20일
  • 2026년 3월 20일
  • 2026년 6월 20일

이 주식 기반 보상 부여는 이사의 이익을 주주와 일치시키며 장기적인 주식 소유 가능성을 제공합니다. 제출은 SEC 요구 기간 내에 이루어져 섹션 16(a) 보고 의무를 준수함을 보여줍니다.

Détails du dépôt du formulaire 4 : Jerome B. Zeldis, directeur de Soligenix (SNGX), a déclaré l'acquisition d'options d'achat d'actions le 20 juin 2025. L'initié a reçu 17 647 options d'achat d'actions avec un prix d'exercice de 1,70 $ par action.

Les options ont une durée de 10 ans, expirant le 20 juin 2035, et seront acquises en quatre versements égaux aux dates suivantes :

  • 20 septembre 2025
  • 20 décembre 2025
  • 20 mars 2026
  • 20 juin 2026

Cette attribution de rémunération en actions aligne les intérêts du directeur avec ceux des actionnaires via un potentiel de détention d'actions à long terme. Le dépôt a été effectué dans les délais requis par la SEC, démontrant la conformité aux obligations de déclaration de la Section 16(a).

Details zur Form 4 Einreichung: Jerome B. Zeldis, Direktor von Soligenix (SNGX), meldete am 20. Juni 2025 den Erwerb von Aktienoptionen. Dem Insider wurden 17.647 Aktienoptionen mit einem Ausübungspreis von 1,70 $ pro Aktie gewährt.

Die Optionen haben eine Laufzeit von 10 Jahren und laufen am 20. Juni 2035 ab. Sie werden in vier gleichen Raten zu folgenden Terminen unverfallbar:

  • 20. September 2025
  • 20. Dezember 2025
  • 20. März 2026
  • 20. Juni 2026

Diese aktienbasierte Vergütung richtet die Interessen des Direktors mit denen der Aktionäre durch langfristiges Aktienbesitzpotenzial aus. Die Meldung erfolgte fristgerecht gemäß den Anforderungen der SEC und entspricht den Berichtspflichten gemäß Abschnitt 16(a).

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ZELDIS JEROME B

(Last) (First) (Middle)
C/O SOLIGENIX, INC.
29 EMMONS DRIVE, SUITE B-10

(Street)
PRINCETON NJ 08540

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SOLIGENIX, INC. [ SNGX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.7 06/20/2025 A 17,647 (1) 06/20/2035 Common Stock 17,647 $0 17,647 D
Explanation of Responses:
1. The stock option vests ratably on each of September 20, 2025, December 20, 2025, March 20, 2026 and June 20, 2026.
/s/ Jerome B. Zeldis 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did SNGX director Jerome Zeldis receive on June 20, 2025?

Jerome Zeldis received 17,647 stock options with an exercise price of $1.70 per share. These options were granted on June 20, 2025, and will expire on June 20, 2035.

What is the vesting schedule for SNGX director Zeldis's June 2025 stock options?

The stock options vest in four equal installments on: September 20, 2025, December 20, 2025, March 20, 2026, and June 20, 2026.

What position does Jerome Zeldis hold at Soligenix (SNGX)?

According to the Form 4 filing, Jerome B. Zeldis serves as a Director of Soligenix (SNGX). This is indicated by the 'X' marked in the Director box under the relationship to issuer section.

How long are Jerome Zeldis's SNGX stock options valid?

The stock options granted to Jerome Zeldis have a 10-year term, with an expiration date of June 20, 2035, as indicated in the derivative securities table of the Form 4.

What was the exercise price of SNGX stock options granted in June 2025?

The stock options were granted with an exercise price of $1.70 per share, as shown in the conversion or exercise price column of the derivative securities table.
Soligenix Inc

NASDAQ:SNGX

SNGX Rankings

SNGX Latest News

SNGX Latest SEC Filings

SNGX Stock Data

4.47M
3.15M
0.03%
1.22%
4.01%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON